TIDMPRTC
PureTech Health PLC
06 June 2022
6 June 2022
PureTech Health plc
PureTech Founded Entity Akili Announces Veteran Life Sciences
Executive Matt Franklin in Newly Created Role of President and
Chief Operating Officer
Franklin brings proven track record leading early
commercialization and growing disruptive healthcare business
models, including at Exact Sciences, Foundation Medicine and Boston
Scientific
Franklin to oversee Akili's Commercial, Product, Engineering,
Medical and People Operations, reporting to CEO Eddie Martucci
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company noted that its
Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading
digital medicine company pioneering the development of cognitive
treatments through game-changing technologies, today announced that
industry veteran Matt Franklin will join the company in the newly
created role of President and Chief Operating Officer, effective
June 21, 2022.
As President and COO, Franklin will join Eddie Martucci, Akili's
Chief Executive Officer, and the company's executive leadership
team to scale the organization and bring Akili's diverse pipeline
of cognitive treatments to market, with an initial focus on the
commercial launch of EndeavorRx(R) . He will lead the day-to-day
operations of the company, and oversee Commercial, Product,
Engineering, Medical and People Operations.
Franklin brings more than two decades of experience across
business, commercial and strategic marketing in the diagnostics,
life sciences and technology industries leading and evolving
innovation. Most recently, Franklin served as General Manager of
the Precision Oncology business unit at Exact Sciences. Previously,
Franklin was the Chief Commercial Officer at Thrive Earlier
Detection Corp, where he led the go-to-market strategy development
for their ground-breaking multi-cancer early detection assay. In
addition, Franklin served as the Chief Business Officer for
ArcherDX, a growth-stage molecular diagnostics company, where he
was responsible for establishing and scaling the global sales,
customer support, marketing, market access, business development
and corporate development teams. Prior to ArcherDX, Franklin served
as the Senior Vice President of Global Marketing and Clinical
Product Strategy at Foundation Medicine where he led the global
launch of three products in three years, including the company's
first liquid biopsy offering and the first FDA-approved,
CMS-covered, comprehensive genomic profiling companion diagnostic
test. Franklin held progressive leadership roles overseeing novel
interventional medical devices at Boston Scientific, culminating in
his running global strategic planning, product development and
marketing for the company's cardiovascular division.
The full text of the announcement from Akili is as follows:
Akili Announces Veteran Life Sciences Executive Matt Franklin in
Newly Created Role of President and Chief Operating Officer
Franklin brings proven track record leading early
commercialization and growing disruptive healthcare business
models, including at Exact Sciences, Foundation Medicine and Boston
Scientific
Franklin to oversee Akili's Commercial, Product, Engineering,
Medical and People operations, reporting to CEO Eddie Martucci
BOSTON, Mass. - June 6, 2022 - Akili Interactive ("Akili"), a
leading digital medicine company pioneering the development of
cognitive treatments through game-changing technologies, today
announced that industry veteran Matt Franklin will join the company
in the newly created role of President and Chief Operating Officer,
effective June 21, 2022.
"As Akili prepares for the commercialization of our first
product later this year, we are thrilled to bring on Matt to help
lead us through this pivotal moment in the company's trajectory,"
said Eddie Martucci, CEO and Co-Founder of Akili Interactive. "Matt
brings more than two decades of experience leading the development
of innovative medical products through launch and commercial
growth. Matt is a strong leader of teams and audacious missions,
and I am confident that Matt's commercial and broader operational
experience will help propel Akili to its next phase of growth and
set us up for long-term success."
As President and COO, Franklin will join Martucci and Akili's
executive leadership team to scale the organization and bring
Akili's diverse pipeline of cognitive treatments to market, with an
initial focus on the commercial launch of EndeavorRx(R) . He will
lead the day-to-day operations of the company, and oversee
Commercial, Product, Engineering, Medical and People
Operations.
"I am honored to join Akili, a company with a pioneering mission
to deliver clinically-validated software-based therapeutics for
patients living with attention dysfunction, a traditionally
underserved area of medicine," said Franklin. "Furthermore, I am
excited to build on Akili's promise to deliver amazing experiences
to patients. I look forward to working with Eddie and the rest of
the executive team to advance Akili's pipeline of innovative
cognitive medicine."
Franklin brings more than two decades of experience across
business, commercial and strategic marketing in the diagnostics,
life sciences and technology industries leading and evolving
innovation. Most recently, Franklin served as General Manager of
the Precision Oncology business unit at Exact Sciences. Previously,
Franklin was the Chief Commercial Officer at Thrive Earlier
Detection Corp, where he led the go-to-market strategy development
for their ground-breaking multi-cancer early detection assay. In
addition, Franklin served as the Chief Business Officer for
ArcherDX, a growth-stage molecular diagnostics company, where he
was responsible for establishing and scaling the global sales,
customer support, marketing, market access, business development
and corporate development teams.
Prior to ArcherDX, Franklin served as the Senior Vice President
of Global Marketing and Clinical Product Strategy at Foundation
Medicine where he led the global launch of three products in three
years, including the company's first liquid biopsy offering and the
first FDA-approved, CMS-covered, comprehensive genomic profiling
companion diagnostic test. Franklin held progressive leadership
roles overseeing novel interventional medical devices at Boston
Scientific, culminating in his running global strategic planning,
product development and marketing for the company's cardiovascular
division.
Franklin began his career as a technology consultant and
software development leader. He holds a B.A. in English literature
from Northwestern University, and an M.B.A. from the University of
Michigan, Ann Arbor.
About Akili
Akili is pioneering the development of cognitive treatments
through game-changing technologies. Our approach of leveraging
technologies designed to directly target the brain establishes a
new category of medicine - medicine that is validated through
clinical trials like a drug or medical device but experienced like
entertainment. Akili's platform is powered by proprietary
therapeutic engines designed to target cognitive impairment at its
source in the brain, informed by decades of research and validated
through rigorous clinical programs. Driven by Akili's belief that
effective medicine can also be fun and engaging, Akili's products
are delivered through captivating action video game experiences.
For more information, please visit www.akiliinteractive.com .
Forward-Looking Statements
This communication may contain certain forward-looking
statements within the meaning of the federal securities laws. These
forward-looking statements generally are identified by the words
"believe," "project," "expect," "anticipate," "estimate," "intend,"
"strategy," "future," "opportunity," "plan," "may," "should,"
"will," "would, " "will be," "will continue," "will likely result,"
and similar expressions and include statements regarding Akili's
expectations for EndeavorRx(R) and digital medicine, the
development of its platform and the launch of EndeavorRx(R).
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
communication, including but not limited to (i) the ability of
Akili to successfully commercialize EndeavorRx(R) and continue to
advance its clinical development pipeline, (ii) the ability of
Akili to maintain relationships with customers and suppliers and
retain its management and key employees, (iii) the evolution of the
markets in which Akili competes, (iv) the ability of Akili to
defend its intellectual property and satisfy regulatory
requirements, (v) the impact of the COVID-19 pandemic on Akili's
business, (vi) Akili's expectations regarding its market
opportunities and (vii) the risk of downturns and a changing
regulatory landscape in the highly competitive industry in which
Akili operates. The foregoing list of factors is not exhaustive.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Akili assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Akili does
not give any assurance that it will achieve its expectations.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders.
This pipeline, which is being advanced both internally and
through PureTech's Founded Entities, is comprised of 27
therapeutics and therapeutic candidates, including two that have
received both U.S. FDA clearance and European marketing
authorization, as of the date of PureTech's most recently filed
Annual Report and corresponding Form 6-K. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those statements that relate to Akili's
expectations for EndeavorRx(R) and digital medicine, the
competitive environment in which Akili operates, and Akili and
PureTech's future prospects, development plans, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks, uncertainties and other
important factors that could cause actual results, performance and
achievements to differ materially from current expectations,
including, but not limited to, those risks, uncertainties and other
important factors described under the caption "Risk Factors" in our
Annual Report on Form 20-F for the year ended December 31, 2021
filed with the SEC and in our other regulatory filings. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the Company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements, we
disclaim any obligation to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
U.S. Media
Nichole Sarkis
+1 774 278 8273
nichole@tenbridgecommunications.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADXGDLRSGDGDU
(END) Dow Jones Newswires
June 06, 2022 02:05 ET (06:05 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024